The volume examines the use of Vyxeos® liposomal (CPX-351) in the treatment of high-risk acute myeloid leukemia, with particular reference to therapy-related AML (t-AML) and AML with myelodysplasia-related changes (AML-MRC). Using a Health Technology Assessment approach, it evaluates the clinical and pharmacoeconomic evidence for Vyxeos® liposomal compared with the standard 7+3 regimen, considering survival, life-years…

The volume presents a series of clinical observations on the use of dimethyl fumarate (DMF) in patients with different forms of moderate-to-severe psoriasis. Through cases from clinical practice, it explores treatment response, dose adjustment, tolerability and the impact of therapy on patients’ quality of life. The clinical experiences include plaque psoriasis, involvement of sensitive areas…